var data={"title":"Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/contributors\" class=\"contributor contributor_credentials\">Arthur Y Kim, MD, FIDSA</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/contributors\" class=\"contributor contributor_credentials\">David L Thomas, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/contributors\" class=\"contributor contributor_credentials\">Allyson Bloom, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Apr 13, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The intersection of the HIV and hepatitis C virus (HCV) epidemics has significant clinical implications and raises many challenging issues for patients and their health care providers [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/1\" class=\"abstract_t\">1</a>]. A thorough understanding of the natural history of liver disease in this complex patient population is critical for optimal management.</p><p>The epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient will be discussed here. (See <a href=\"topic.htm?path=evaluation-of-the-hiv-infected-patient-with-chronic-hepatitis-c-virus-infection\" class=\"medical medical_review\">&quot;Evaluation of the HIV-infected patient with chronic hepatitis C virus infection&quot;</a> and <a href=\"topic.htm?path=treatment-of-chronic-hepatitis-c-virus-infection-in-the-hiv-infected-patient\" class=\"medical medical_review\">&quot;Treatment of chronic hepatitis C virus infection in the HIV-infected patient&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">VIROLOGY OF HCV</span></p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Viral kinetics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>HIV (a retrovirus) and HCV (a flavivirus) are RNA viruses. The viral kinetics of HIV and HCV have been determined by perturbation of the steady-state between virus production and clearance with potent antiviral agents [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/2,3\" class=\"abstract_t\">2,3</a>]. HIV viral production rates approximate 10(10) virions a day with a half-life of less than six hours [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/2\" class=\"abstract_t\">2</a>]. Virion production rates are even greater with HCV, approaching 10(12) virions a day with a virion half-life of 2.7 hours [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/3\" class=\"abstract_t\">3</a>].</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Viral load</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>During the chronic stage of either HIV or HCV infection, a relatively stable viral load or &quot;set point&quot; is maintained [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/4,5\" class=\"abstract_t\">4,5</a>]. However, in the setting of combined infection, HCV RNA levels increase after HIV seroconversion and continue to increase over time compared with patients with HCV alone [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/6-8\" class=\"abstract_t\">6-8</a>]. The level of HCV viremia is inversely correlated with lower CD4 counts in most, but not all studies [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/7,9\" class=\"abstract_t\">7,9</a>] and may transiently increase with initiation of antiretroviral therapy (ART) or heavy alcohol use [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/10\" class=\"abstract_t\">10</a>]. Overall increases in the HCV viral load do not have implications for the severity of liver-related disease, but do have an impact on treatment response. (See <a href=\"topic.htm?path=evaluation-of-the-hiv-infected-patient-with-chronic-hepatitis-c-virus-infection\" class=\"medical medical_review\">&quot;Evaluation of the HIV-infected patient with chronic hepatitis C virus infection&quot;</a>.)</p><p>One study evaluated whether higher levels of HCV viremia in HIV-infected patients may be related to immunosuppression [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/11\" class=\"abstract_t\">11</a>]. The researchers reasoned that if high levels of replication were due to decreased immune selective pressure, then a reduced rate of nucleotide changes would be expected within the virus itself. However, in an investigation of HCV envelope sequences in 79 patients, with or without HIV coinfection, no significant divergence was demonstrated over time between the two groups. Another way HIV infection may increase HCV replication is through the virus itself; one in vitro study demonstrated that the envelope protein of HIV (gp120) increased HCV replication through engagement of cellular coreceptors of HIV (ie, CXCR4 or CCR5) [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/12\" class=\"abstract_t\">12</a>].</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Viral reservoirs</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>HIV replicates in many cell types in addition to CD4+ T-cells [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/13\" class=\"abstract_t\">13</a>]. More controversial is whether HCV also replicates in extrahepatic sites such as peripheral blood mononuclear cells (PBMCs) [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/14\" class=\"abstract_t\">14</a>]. While some studies have documented HCV RNA-negative strands (the viral replicative intermediate) in PBMCs, others have not confirmed this finding [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/15,16\" class=\"abstract_t\">15,16</a>]. Some have suggested that HCV RNA replication in PBMCs may occur in <span class=\"nowrap\">HIV/HCV-coinfected</span> patients, but not in those with HCV alone [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/17\" class=\"abstract_t\">17</a>].</p><p>The implications for HIV-infected patients are unclear, but in other chronic infections (eg, tuberculosis and cytomegalovirus), continuous activation of the immune system can lead to an increase in activated CD4+ T-cells, which are preferential targets of HIV [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/18,19\" class=\"abstract_t\">18,19</a>]. HCV replication in PBMCs or dendritic cells could also be a mechanism for the relapse of HCV viremia that is seen in HIV-infected patients after treatment is discontinued [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/16\" class=\"abstract_t\">16</a>].</p><p>HCV has also been isolated from cervicovaginal lavage fluid [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/20\" class=\"abstract_t\">20</a>] in HIV-seropositive women, but not in women with HCV alone [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/21\" class=\"abstract_t\">21</a>]. This may explain the higher rates of perinatal HCV transmission observed in the setting of coinfection. (See <a href=\"#H7\" class=\"local\">'Epidemiology'</a> below.)</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Genetic heterogeneity</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Single-stranded RNA viruses, like HIV and HCV, lack proofreading mechanisms, resulting in high mutational rates [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/22\" class=\"abstract_t\">22</a>]. This leads to the formation of genetically distinct viral variants that collectively comprise a &quot;quasispecies.&quot; Whether a particular nucleotide substitution results in a replication-competent mutant depends upon the involved site.</p><p>With HIV, it is estimated that all possible single-point mutations occur between 10(4) and 10(5) times per day in an infected individual [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/23\" class=\"abstract_t\">23</a>]. This leads to a large pool of genetic variants able to adapt rapidly to changing selective drug pressures [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/24\" class=\"abstract_t\">24</a>].</p><p>During replication of HCV, RNA-dependent RNA polymerase frequently introduces random nucleotide errors, resulting in a high rate of spontaneous nucleotide substitutions [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/25\" class=\"abstract_t\">25</a>]. Like HIV, sequence heterogeneity is concentrated in certain regions, such as the first hypervariable region (HVR1) of the E2 gene, which encodes the envelope protein of HCV [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/26\" class=\"abstract_t\">26</a>]. This is analogous to the hypervariable region in the V3 loop of gp120, the envelope protein of HIV [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/27\" class=\"abstract_t\">27</a>]. Increased sequence variability of the E2 HVR of the HCV genome has been noted in <span class=\"nowrap\">HIV/HCV-coinfected</span> individuals when compared with HCV-infected individuals [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/26\" class=\"abstract_t\">26</a>].</p><p>These similarities between HIV and HCV viral diversity have treatment implications. The extent of the quasispecies evolution in an individual and the level of viremia have been implicated as predictors of response to interferon [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/26,28\" class=\"abstract_t\">26,28</a>]. In one study of <span class=\"nowrap\">HIV/HCV</span> coinfected patients, lower quasispecies complexity of HCV was associated with earlier viral clearance in response to interferon-based regimens [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/29\" class=\"abstract_t\">29</a>]. Furthermore, there is evidence of different evolution of the quasispecies of HCV in various compartments as has been noted for HIV [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/30\" class=\"abstract_t\">30</a>].</p><p>The potential for HCV drug resistance parallels that of HIV, as demonstrated with the introduction of directly-acting antiviral agents against HCV (eg, DAAs) [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/31\" class=\"abstract_t\">31</a>]. As described in the past with HIV, resistance mutations to specific HCV protease and polymerase inhibitors have been identified even in treatment-naive HCV and <span class=\"nowrap\">HIV/HCV-coinfected</span> patients [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/32,33\" class=\"abstract_t\">32,33</a>]. Resistance-associated substitutions and their impact on response to specific DAAs are discussed in detail elsewhere. (See <a href=\"topic.htm?path=direct-acting-antivirals-for-the-treatment-of-hepatitis-c-virus-infection\" class=\"medical medical_review\">&quot;Direct-acting antivirals for the treatment of hepatitis C virus infection&quot;</a> and <a href=\"topic.htm?path=predictors-of-response-to-antiviral-therapy-for-chronic-hepatitis-c-virus-infection#H2889683800\" class=\"medical medical_review\">&quot;Predictors of response to antiviral therapy for chronic hepatitis C virus infection&quot;, section on 'Resistance-associated substitutions'</a>.) </p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Coinfection with HIV and HCV is common since both infections share similar routes of transmission. In a meta-analysis of over 780 studies evaluating HIV-infected populations worldwide, the overall prevalence of HCV coinfection was estimated to be approximately 6 percent [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/34\" class=\"abstract_t\">34</a>]. There was substantial geographic variation, with Central and Eastern Europe estimated to account for 27 percent of the global population of coinfected individuals. In the United States and Western Europe, studies have suggested that approximately 30 percent of HIV-infected patients are also infected with HCV [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/35,36\" class=\"abstract_t\">35,36</a>]. </p><p>Because the relative efficiency of HCV transmission differs by route, the prevalence of coinfection varies markedly across risk groups, with much higher rates in people who inject drugs compared with those whose HIV exposure was through heterosexual sex. The sequence of infections also depends on transmission route. For example, injection drug users usually acquire HCV before HIV infection while men who have sex with men (MSM) typically are infected with HIV before they acquire HCV infection [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/37,38\" class=\"abstract_t\">37,38</a>].</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Percutaneous exposure</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>HCV is transmitted efficiently via percutaneous routes, so seroprevalence rates are highest in injection drug users and hemophiliacs who received contaminated blood products prior to the introduction of HCV screening in 1990. Injection drug use is the leading route of HCV transmission in resource-rich settings, since the risk of post-transfusion HCV infection is now extremely low. Approximately 50 to 90 percent of drug users are infected with HCV after sharing contaminated needles or drug paraphernalia [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/39\" class=\"abstract_t\">39</a>]. Globally, an estimated 80 percent of HIV-infected individuals with a history of injection drug use have evidence of HCV coinfection [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/34\" class=\"abstract_t\">34</a>]. </p><p>In the United States, increases in injection behaviors have resulted in rising incidence of HCV infection and more individuals at risk for <span class=\"nowrap\">HIV/HCV</span> coinfection. In 2015, in and around Scott County, Indiana, an investigation of a cluster of HIV cases resulted in identification of 135 new diagnoses of HIV, with HCV coinfection present in 114 (84.4 percent), among a community of 4200 residents [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/40\" class=\"abstract_t\">40</a>]. This outbreak was linked to injection of <a href=\"topic.htm?path=oxymorphone-drug-information\" class=\"drug drug_general\">oxymorphone</a> and lack of local harm prevention services. (See <a href=\"topic.htm?path=epidemiology-and-transmission-of-hepatitis-c-virus-infection#H4\" class=\"medical medical_review\">&quot;Epidemiology and transmission of hepatitis C virus infection&quot;, section on 'Injection drug use'</a>.)</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Heterosexual partners</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Among heterosexual partners, HIV is much more easily transmissible than HCV via intercourse [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/41,42\" class=\"abstract_t\">41,42</a>]. The risk of HCV transmission is exceedingly low in monogamous couples [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/43\" class=\"abstract_t\">43</a>], but appears to increase in patients who report multiple sexual partners [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/39,44\" class=\"abstract_t\">39,44</a>]. Globally, the prevalence of HCV coinfection is approximately 4 percent among individuals whose main HIV exposure risk was through heterosexual sex [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/34\" class=\"abstract_t\">34</a>].</p><p>Whether underlying HIV infection increases the risk of heterosexual HCV transmission to an uninfected partner is unclear due to contradictory study results [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/45-47\" class=\"abstract_t\">45-47</a>]. (See <a href=\"topic.htm?path=epidemiology-and-transmission-of-hepatitis-c-virus-infection#H9\" class=\"medical medical_review\">&quot;Epidemiology and transmission of hepatitis C virus infection&quot;, section on 'Sexual or household contact'</a>.)</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Men who have sex with men</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The global prevalence of HCV coinfection among HIV-infected men who have sex with men (MSM) is estimated to be 6.4 percent, but this varies by geographic region [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/34\" class=\"abstract_t\">34</a>]. The seroprevalence of HCV in HIV-infected MSM in the United States ranges from about 4 to 8 percent [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/48,49\" class=\"abstract_t\">48,49</a>], which is similar to that found in HIV-uninfected MSM [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/50\" class=\"abstract_t\">50</a>] but higher than that reported for the entire population (1.8 percent) [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/51\" class=\"abstract_t\">51</a>]. In contrast, in a study of 689 MSM from the Netherlands, HCV prevalence was 0.4 percent among HIV-uninfected MSM and 18 percent among HIV-infected MSM [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/52\" class=\"abstract_t\">52</a>]. Over the study period, HCV prevalence among HIV-infected MSM increased significantly (15 to 21 percent). Among a cohort of 3333 HIV-infected MSM, HCV incidence increased 18-fold from 1998 to 2011 [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/53\" class=\"abstract_t\">53</a>]. </p><p>Accumulating data from the United States and Europe suggest that an increased risk of HCV transmission exists among MSM whose predominant risk factor is unsafe sex [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/48,53-58\" class=\"abstract_t\">48,53-58</a>]. Molecular methodology has been useful in identifying transmission clusters of HCV [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/58-60\" class=\"abstract_t\">58-60</a>]. For example, phylogenetic analysis of genotype 4 HCV virus in 12 HIV-infected MSM found that 10 had an identical source of infection, which appeared to be sexually transmitted [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/59\" class=\"abstract_t\">59</a>]. New HCV infections appear to be especially common among HIV-infected MSM; HCV transmission may be enhanced by mucosal injury <span class=\"nowrap\">and/or</span> concomitant sexually transmitted diseases. [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/44\" class=\"abstract_t\">44</a>]. Among MSM, unprotected anal sex, fisting, group sex, and recreational drugs (eg, gamma hydroxy butyrate) [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/52\" class=\"abstract_t\">52</a>] are associated with HCV acquisition [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/52,58,60-62\" class=\"abstract_t\">52,58,60-62</a>]. The importance of mucosal damage as a risk factor for HCV acquisition was highlighted in a report in which 18 of 20 MSM reported either genital ulcerative disease (lymphogranuloma venereum, syphilis, or HSV-2) or fisting within the period of acute HCV seroconversion [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/55\" class=\"abstract_t\">55</a>]. HCV is not as common among HIV-uninfected MSM. As an example, in a large cohort of MSM in the United States, HIV-infection was associated with a six-fold increase in HCV incidence [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/63\" class=\"abstract_t\">63</a>].</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Perinatal transmission</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Vertical transmission of HCV appears to be facilitated by HIV-coinfection. A meta-analysis of 10 studies demonstrated that maternal coinfection increases the odds of vertical HCV transmission by approximately 90 percent (odds ratio, 1.9; 95% CI 1.4-2.7), compared with maternal HCV infection alone [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/64\" class=\"abstract_t\">64</a>]. (See <a href=\"topic.htm?path=vertical-transmission-of-hepatitis-c-virus\" class=\"medical medical_review\">&quot;Vertical transmission of hepatitis C virus&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Health care workers</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are rare case reports of health care workers who have simultaneously acquired HIV and HCV via percutaneous exposure [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/65\" class=\"abstract_t\">65</a>]. (See <a href=\"topic.htm?path=prevention-of-hepatitis-b-virus-and-hepatitis-c-virus-infection-among-healthcare-providers\" class=\"medical medical_review\">&quot;Prevention of hepatitis B virus and hepatitis C virus infection among healthcare providers&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h1\">PATHOGENESIS OF LIVER DISEASE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><span class=\"nowrap\">HIV/HCV-coinfected</span> patients have accelerated rates of fibrosis progression compared with patients with HCV alone. Insight into the mechanisms that underlie the immunopathogenesis of these persistent viral infections could lead to new therapeutic strategies [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/38\" class=\"abstract_t\">38</a>].</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h2\">Cellular immune responses</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Liver fibrosis progression may be related to weak cellular immune responses to HCV antigens in HIV-infected patients. HIV infection is characterized by marked decreases in the number of circulating CD4 cells, functional impairment of both CD4 and CD8 cells, and down-regulation of CD28 expression, a costimulatory molecule required for effective lymphocyte activation [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/66\" class=\"abstract_t\">66</a>]. Patients with low absolute CD4+ T-cell counts have a diminished frequency of HCV-specific CD8+ T-cell responses [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/67\" class=\"abstract_t\">67</a>]. This observation provides a possible link between advanced immunosuppression and liver disease progression since CD8+ T-cell responses are thought to be of primary importance in the immune response to viral infection. Furthermore, successful antiretroviral therapy (ART) may restore cellular immune responses to HCV antigens [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/68\" class=\"abstract_t\">68</a>].</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h2\">HIV-associated immune activation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Another hypothesis suggests that chronic immune activation, secondary to HIV infection, influences liver disease progression through increased circulation of pro-inflammatory cytokines.</p><p>Chronic immune activation may be mediated by translocation of microbial products due to impaired gut mucosal integrity [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/69\" class=\"abstract_t\">69</a>]. Disruption of mucosal barriers occurs in conjunction with severe CD4 depletion in gut-associated lymphoid tissue during early HIV infection. Translocation of microbial products is inferred by high circulating levels of serum lipopolysaccharide; in contrast, treatment with ART reduces LPS levels.</p><p>One study of <span class=\"nowrap\">HIV/HCV-coinfected</span> patients found that CD4 lymphocyte depletion was strongly associated with markers of microbial translocation (eg, LPS, soluble CD14, and others); these markers were also associated with the development of cirrhosis [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/70\" class=\"abstract_t\">70</a>]. The development of fibrosis may be related to Kupffer cell depletion, which is directly associated with CD4 T cell decline [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/71\" class=\"abstract_t\">71</a>].</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h2\">Activation of hepatic stellate cells</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Activated hepatic stellate cells (HSCs) mediate collagen formation in hepatitis C virus (HCV)-related liver fibrosis. One study found that HSC activation levels were directly associated with CD4 and CD8 T cell immune activation and enhanced interleukin-15 (IL-15) gene expression, suggesting a pathogenic role for IL-15 in mediating liver fibrosis progression in <span class=\"nowrap\">HIV/HCV-coinfected</span> patients [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/72\" class=\"abstract_t\">72</a>].</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h2\">HIV and apoptosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediates apoptosis in normal hepatocytes and is upregulated during HCV infection [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/73\" class=\"abstract_t\">73</a>]. One in vitro study has suggested that glycoproteins of HIV (ie, gp120) may sensitize hepatocytes to cell death through upregulation of TRAIL-mediated apoptosis [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/74\" class=\"abstract_t\">74</a>].</p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h2\">HCV-associated proinflammatory cytokines</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>HCV infection itself induces immunoregulatory and proinflammatory pathways that may contribute to progression of liver fibrosis [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/72\" class=\"abstract_t\">72</a>]. These same proinflammatory cytokines may have a deleterious effect on HIV disease as well. (See <a href=\"#H27\" class=\"local\">'Effect of HCV on the natural history of HIV'</a> below.)</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h1\">EFFECT OF HIV ON THE NATURAL HISTORY OF HCV</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In patients with chronic HCV infection, concomitant HIV infection is associated with higher rates of morbidity and mortality related to liver disease [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/75,76\" class=\"abstract_t\">75,76</a>]. <span class=\"nowrap\">HIV/HCV</span> coinfected patients are less likely to clear viral infection, have more rapid rates of fibrosis, and have a higher risk of hepatic decompensation compared with HCV monoinfected patients. </p><p>These cumulative observations led the United States Public Health Service to recommend that all patients with HIV undergo testing for HCV [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/77\" class=\"abstract_t\">77</a>]. Treatment, with a sustained virologic response (SVR), may alter disease outcomes [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/78\" class=\"abstract_t\">78</a>]. (See <a href=\"#H28\" class=\"local\">'Screening for HCV infection'</a> below and <a href=\"topic.htm?path=evaluation-of-the-hiv-infected-patient-with-chronic-hepatitis-c-virus-infection\" class=\"medical medical_review\">&quot;Evaluation of the HIV-infected patient with chronic hepatitis C virus infection&quot;</a>.)</p><p>In addition, effective antiretroviral therapy (ART) of HIV among coinfected patients is associated with better clinical outcomes, supporting early initiation of ART in this population. (See <a href=\"topic.htm?path=when-to-initiate-antiretroviral-therapy-in-hiv-infected-patients\" class=\"medical medical_review\">&quot;When to initiate antiretroviral therapy in HIV-infected patients&quot;</a>.) </p><p class=\"headingAnchor\" id=\"H20\"><span class=\"h2\">Viral clearance</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>HIV-infected patients have lower rates of spontaneous virologic clearance during acute infection, especially in the setting of lower CD4 cell counts, which in turn may be associated with impaired immune responses to HCV antigens [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/79-81\" class=\"abstract_t\">79-81</a>].</p><p class=\"headingAnchor\" id=\"H21\"><span class=\"h2\">Fibrosis progression rates</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with HCV and HIV coinfection have a relatively rapid rate of progression to cirrhosis, greater than that observed in most patients with HCV infection alone [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/82-85\" class=\"abstract_t\">82-85</a>]. </p><p>Studies of paired biopsy findings in coinfected patients suggest that a high proportion have progressive fibrosis, even if minimal disease is detected at baseline. In a cohort of 282 <span class=\"nowrap\">HIV/HCV</span> coinfected patients without cirrhosis who underwent at least two liver biopsies as part of medical care, no or minimal fibrosis (METAVIR stage F0 or F1) was identified on the initial biopsy among 243 individuals (86 percent) [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/86\" class=\"abstract_t\">86</a>]. With a median interval of 2.5 years between biopsies, progression of at least one METAVIR stage was observed in 34 percent, and progression of two or more stages was observed in 9 percent. These results are consistent with prior, smaller studies of <span class=\"nowrap\">HCV/HIV</span> coinfected patients with paired liver biopsies that suggested that 25 to 50 percent of patients had progression of fibrosis over a median of approximately three years [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/87,88\" class=\"abstract_t\">87,88</a>]. Rapid progression to cirrhosis has also been reported among HIV-infected men who have sex with men who are subsequently infected with HCV [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/85\" class=\"abstract_t\">85</a>]. </p><p>Such fibrosis progression rates are higher than those reported among HCV monoinfected patients [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/89\" class=\"abstract_t\">89</a>]. As an example, in a study of 122 <span class=\"nowrap\">HIV/HCV</span> coinfected and 122 HCV monoinfected patients, matched for age, sex, alcohol use, age at HCV infection, and duration of HCV infection, the prevalence of extensive liver fibrosis on biopsy was greater among coinfected patients (54 versus 30 percent in monoinfected patients) [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/82\" class=\"abstract_t\">82</a>].</p><p>Noninvasive assessments of liver fibrosis can be performed more frequently than biopsy, and studies employing these techniques have also suggested more rapid progression of fibrosis with coinfection. In one study of HCV-infected injection drug users who underwent routine longitudinal liver elastography, participants with HIV infection had liver fibrosis measurements equivalent to those observed in HIV-uninfected participants who were almost a decade older [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/84\" class=\"abstract_t\">84</a>]. (See <a href=\"topic.htm?path=noninvasive-assessment-of-hepatic-fibrosis-overview-of-serologic-and-radiographic-tests#H235753281\" class=\"medical medical_review\">&quot;Noninvasive assessment of hepatic fibrosis: Overview of serologic and radiographic tests&quot;, section on 'Imaging tests'</a>.)</p><p>However, not all studies have documented more severe liver fibrosis among coinfected compared with monoinfected patients [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/90\" class=\"abstract_t\">90</a>]. One possible explanation for these discrepant findings may be related to varying degrees of HIV-related immunosuppression in the patient populations.</p><p class=\"headingAnchor\" id=\"H46114182\"><span class=\"h3\">Risk factors for progression</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>As in HCV monoinfected patients, certain clinical characteristics, such as older age, alcohol use, diabetes, high body mass index (BMI), and elevated serum aspartate aminotransferase levels, have been associated with fibrosis progression among <span class=\"nowrap\">HIV/HCV</span> coinfected patients [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/82,84,87,88,91\" class=\"abstract_t\">82,84,87,88,91</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-and-natural-history-of-chronic-hepatitis-c-virus-infection#H11\" class=\"medical medical_review\">&quot;Clinical manifestations and natural history of chronic hepatitis C virus infection&quot;, section on 'Factors associated with disease progression'</a>.)</p><p>Steatosis (fatty liver) has also been associated with an increased risk of fibrosis progression among both monoinfected and <span class=\"nowrap\">HIV/HCV</span> coinfected patients [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/92-94\" class=\"abstract_t\">92-94</a>]. Moreover, steatosis appears to be more common in coinfected patients [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/93\" class=\"abstract_t\">93</a>]. Steatosis among HIV-infected patients may be related to a variety of factors, including genotype 3 infection, ART, or metabolic factors, such as visceral obesity and insulin resistance [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/92,95\" class=\"abstract_t\">92,95</a>].</p><p>HIV-associated factors that have been associated with fibrosis progression in most [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/82,84,88,91,96\" class=\"abstract_t\">82,84,88,91,96</a>], but not all studies [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/86\" class=\"abstract_t\">86</a>], include CD4 cell count &lt;200 <span class=\"nowrap\">cells/microL,</span> HIV viremia, and lack of ART.</p><p class=\"headingAnchor\" id=\"H10494880\"><span class=\"h3\">Relationship of liver disease stage and clinical outcome</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The risk of liver-related morbidity and mortality in an individual HCV-infected patient is an important consideration in management decisions. As in monoinfected patients, this risk increases with the severity of liver fibrosis.</p><p>In a prospective cohort of 638 coinfected patients (80 percent African-American), the risk of incident end-stage liver disease, hepatocellular carcinoma, or death was associated with the initial stage of fibrosis on liver biopsy evaluation [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/97\" class=\"abstract_t\">97</a>]. Biopsies were scored for fibrosis stage according to the METAVIR system: F0, no fibrosis; F1, portal fibrosis without septa; F2, portal fibrosis with few septa; F3, numerous septa without cirrhosis; and F4, cirrhosis. The following findings were noted: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Compared with F0, the incidence rate ratio (IRR) was 2.31 for F2 (95% CI, 1.2-4.3); 3.2 for F3 (95% CI, 1.5-6.9); and 3.6 for F4 (95% CI, 2.1-6.2). </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Among the 226 patients who underwent HCV treatment, the incidence of clinical events in treatment nonresponders was not different from untreated patients. In contrast, no clinical events were observed in the 51 patients with SVR or relapse, including 19 with significant disease at baseline.</p><p/><p>The actual risk of liver decompensation in the setting of fibrosis was assessed in a retrospective analysis of 892 <span class=\"nowrap\">HIV/HCV</span> coinfected patients with advanced fibrosis and a median follow-up of 5.4 years [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/98\" class=\"abstract_t\">98</a>]. The rates of hepatic decompensation were 2.3 and 4.0 events per 100 person-years among those with advanced fibrosis determined by biopsy and transient elastography, respectively. The rates of decompensation were higher among those with cirrhosis (3.1 and 4 events per 100 person-years) compared to those with the equivalent of stage F3 disease (1.4 and 0.9 events per 100 person-years). </p><p class=\"headingAnchor\" id=\"H46114332\"><span class=\"h2\">Hepatocellular carcinoma</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>HCC is an emerging complication in the HIV-infected population. Proportions of liver-related deaths among HIV-infected patients that were attributable to HCC increased from 15 to 25 percent in France from 2000 to 2005 [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/99\" class=\"abstract_t\">99</a>]. Similarly, in a study from Spain, the incidence of HCC among HIV-infected patients increased from 0.1 to 1.1 cases per 1000 person years between 1999 and 2009 [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/100\" class=\"abstract_t\">100</a>]. Almost all of the cases were associated with HCV coinfection. In a prospective, observational cohort in the United States, the incidence of liver cancer was eightfold higher in HIV-infected patients compared with the general population [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/101\" class=\"abstract_t\">101</a>]. </p><p>Data from the United States and Europe suggest that hepatocellular carcinoma (HCC) occurs at a younger age and is associated with shorter survival in <span class=\"nowrap\">HIV/HCV-coinfected</span> patients compared with those with HCV infection alone [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/102,103\" class=\"abstract_t\">102,103</a>]. In addition, a multicenter study in the United States and Canada also confirmed that progression from initial HCV infection to HCC was significantly faster in coinfected patients (26 years) than in HCV-monoinfected patients (34 years) [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/104\" class=\"abstract_t\">104</a>]. Whether HIV confers an independent risk factor to progression to HCC apart from a higher rate of fibrosis progression is unknown.</p><p class=\"headingAnchor\" id=\"H46115818\"><span class=\"h2\">Hepatic decompensation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Underlying HIV infection is also associated with a greater risk of liver decompensation among patients with HCV infection, even in the setting of ART [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/89\" class=\"abstract_t\">89</a>]. </p><p>As an example, a retrospective study of over 10,000 HCV-infected male US veterans evaluated the effect of HIV coinfection on the rate of hepatic decompensation, defined by the diagnosis of ascites, spontaneous bacterial peritonitis, or esophageal hemorrhage [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/105\" class=\"abstract_t\">105</a>]. Decompensation was more frequent among the 4280 ART-treated <span class=\"nowrap\">HIV/HCV</span> coinfected than the 6079 HCV monoinfected patients (6.3 versus 5.0 percent, adjusted HR 1.83, 95% CI 1.54-2.18). The estimated cumulative 10-year incidence of decompensation was 7.4 versus 4.8 percent for coinfected and monoinfected individuals, respectively. </p><p>Even though <span class=\"nowrap\">HCV/HIV</span> coinfected patients on ART appear to be at higher risk of liver decompensation compared with the HIV-uninfected, the risk is even greater in the absence of ART. In another study of over 10,000 <span class=\"nowrap\">HIV/HCV</span> coinfected male US veterans with a median of 3 years of follow-up, 6.4 percent were diagnosed with hepatic decompensation (1.4 events per 100 person-years) [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/106\" class=\"abstract_t\">106</a>]. The risk of decompensation was lower among the 6935 individuals who initiated ART compared with those who did not (HR 0.72, 95% CI 0.54-0.94). Ascites was the most frequent decompensation-defining event.</p><p>Other risk factors for hepatic decompensation among <span class=\"nowrap\">HIV/HCV</span> coinfected patients included baseline advanced fibrosis by noninvasive measures, baseline hemoglobin &lt;10 <span class=\"nowrap\">g/dL,</span> diabetes, untreated HBV infection, and poor CD4 cell increase following ART initiation [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/105,107-109\" class=\"abstract_t\">105,107-109</a>]. (See <a href=\"#H10494880\" class=\"local\">'Relationship of liver disease stage and clinical outcome'</a> above.)</p><p class=\"headingAnchor\" id=\"H24\"><span class=\"h2\">Mortality</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Given the high rates of fibrosis progression and decompensated liver disease among <span class=\"nowrap\">HIV/HCV</span> coinfected patients, liver-related mortality is high among HIV-infected patients [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/75,76,89,110,111\" class=\"abstract_t\">75,76,89,110,111</a>].</p><p>In a prospective observational international study of 23,441 HIV-infected patients who were followed for five years (Data Collection on Adverse Events of Anti-HIV drugs, the D:A:D Study), there were 1246 deaths; 14.5 percent were related to chronic viral hepatitis [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/76\" class=\"abstract_t\">76</a>]. A strong association was found between mortality from liver disease and advanced immunosuppression. Similarly, in a study of 3990 HIV-infected patients from Denmark from 1995 to 2005, persons with <span class=\"nowrap\">HIV/HCV</span> coinfection had considerably higher mortality rates than those who were HCV-uninfected (mortality rate, 59 versus 39 per 1000 person-years) [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/110\" class=\"abstract_t\">110</a>]. Furthermore, the widening gap in mortality rates was even more significant in the late ART period from 2000 to 2005 (mortality rate, 57 per 1000 person-years versus 19 per 1000 person-years).</p><p>In one study, the median survival time after diagnosis of decompensated liver disease in <span class=\"nowrap\">HIV/HCV</span> coinfected patients ranged from only 13 to 16 months [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/112\" class=\"abstract_t\">112</a>]. </p><p class=\"headingAnchor\" id=\"H46115450\"><span class=\"h2\">Effect of ART on HCV progression</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Some [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/113\" class=\"abstract_t\">113</a>], but not all studies [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/114,115\" class=\"abstract_t\">114,115</a>], have suggested that the introduction of potent ART has been associated with a decline in liver-related mortality and slower rates of fibrosis progression. ART may slow down disease progression due to immune reconstitution [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/116\" class=\"abstract_t\">116</a>]. </p><p>In an observational study of 638 <span class=\"nowrap\">HIV/HCV-coinfected</span> patients, 69 percent of whom were taking ART, viral suppression was associated with a lower risk of end-stage liver disease, hepatocellular carcinoma, and death [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/97\" class=\"abstract_t\">97</a>]. Similarly, in a large retrospective study of over 10,000 <span class=\"nowrap\">HIV/HCV</span> coinfected men, ART use was associated with an approximately 28 percent lower likelihood of hepatic decompensation. (See <a href=\"#H46115818\" class=\"local\">'Hepatic decompensation'</a> above.)</p><p>Another study demonstrated that fibrosis progression rates were slower in patients who had achieved HIV viral load suppression on ART compared with those who still had detectable viremia on therapy, suggesting that HIV viral suppression is important as well [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/117\" class=\"abstract_t\">117</a>]. A subsequent cross-sectional study also demonstrated that viral suppression on ART was associated with lower necroinflammatory activity on liver biopsy specimens while another retrospective study demonstrated that ART interruption was associated with an increased risk of fibrosis progression [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/118,119\" class=\"abstract_t\">118,119</a>]. Despite improvements with ART, HIV coinfected persons experience higher rates of fibrosis and, if cirrhotic, higher rates of liver decompensation compared with HIV negative HCV-infected controls [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/84,105\" class=\"abstract_t\">84,105</a>]. (See <a href=\"#H21\" class=\"local\">'Fibrosis progression rates'</a> above and <a href=\"#H46115818\" class=\"local\">'Hepatic decompensation'</a> above.)</p><p>Early initiation of ART in HIV-infected patients is associated with an overall decrease in AIDS and non-AIDS related morbidity and mortality. This approach may be especially relevant for <span class=\"nowrap\">HCV/HIV</span> coinfected patients, particularly in those who are unable or unwilling to take HCV antiviral therapy [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/120\" class=\"abstract_t\">120</a>]. This issue is discussed in detail elsewhere. (See <a href=\"topic.htm?path=when-to-initiate-antiretroviral-therapy-in-hiv-infected-patients\" class=\"medical medical_review\">&quot;When to initiate antiretroviral therapy in HIV-infected patients&quot;</a>.)</p><p>There are conflicting data as to whether any particular drug or class of antiretrovirals affect liver fibrosis progression rates [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/121,122\" class=\"abstract_t\">121,122</a>].</p><p class=\"headingAnchor\" id=\"H27\"><span class=\"h1\">EFFECT OF HCV ON THE NATURAL HISTORY OF HIV</span></p><p class=\"headingAnchor\" id=\"H1660499362\"><span class=\"h2\">HIV progression</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are conflicting results as to whether HCV infection does [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/7,123-126\" class=\"abstract_t\">7,123-126</a>] or does not [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/127,128\" class=\"abstract_t\">127,128</a>] have a deleterious effect on the course of HIV infection.</p><p>The following examples illustrate the range of findings in the largest reports:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a prospective cohort study of 1955 patients, no difference was detected in the risk of acquiring an AIDS-defining illness (ADI) or the risk of death when comparing HCV-infected or HCV-uninfected patients [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/127\" class=\"abstract_t\">127</a>]. The findings were not affected by whether or not the patient was treated with antiretroviral therapy (ART).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>By contrast, in a study of 3111 antiretroviral-na&iuml;ve patients who initiated ART, HCV seropositivity was an independent risk factor for progression to a new AIDS-defining clinical event or to death [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/117\" class=\"abstract_t\">117</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Increased mortality was also seen in a retrospective study of 5914 HIV-infected patients, 37 percent of whom were HCV-positive [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/126\" class=\"abstract_t\">126</a>]. Compared with the general population, the standardized mortality rate (SMR) was 11.5 for HCV-positive patients, and 2.4 for HCV-negative patients. Among the patients with HCV coinfection and AIDS, the SMR was 20.8, compared with 4.8 for those with AIDS who were HCV-negative.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In another retrospective study of 5397 HIV-infected patients (half of whom were HCV-seropositive), the incidence of new ADIs was significantly higher in the HCV-seropositive group compared with the HCV-seronegative group (adjusted relative risk [ARR], 2.61; 95% CI 1.88-3.61). The rate of mycotic infection, bacterial infection, toxoplasmosis, and HIV-related ADIs among patients with cirrhosis were significantly higher than HCV-infected patients without cirrhosis and patients with HIV alone [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/129\" class=\"abstract_t\">129</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a multicenter cohort of 9164 HIV-infected patients whose date of HIV seroconversion was known, evidence of HCV infection (positive antibody or RNA) was independently associated with an increase in AIDS-related mortality (adjusted HR 2.43, 95% CI 1.14-5.20) [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/130\" class=\"abstract_t\">130</a>]. This association persisted across groups with varying HIV risk factors (eg, injection drug use, heterosexual, MSM, hemophilia). </p><p/><p>The factors responsible for these disparate findings are not well understood, although one factor may be HCV viral load [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/7,125,131,132\" class=\"abstract_t\">7,125,131,132</a>]. Two studies have demonstrated a relationship between higher HCV RNA levels and increased risk of clinical progression to AIDS and AIDS-related mortality [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/7,133\" class=\"abstract_t\">7,133</a>]. HCV replication may result in generalized immune activation, which is associated with shorter survival in HIV-infected patients [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/133,134\" class=\"abstract_t\">133,134</a>]. One study also demonstrated that the rate of CD4 cell gains was lower among patients who had chronic HCV infection compared with those who had spontaneously cleared their viremia [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/135\" class=\"abstract_t\">135</a>]. Immune activation, with subsequent T-cell apoptosis, could also explain the observation that CD4+ gains after antiretroviral therapy (ART) initiation are generally lower in coinfected patients compared with those with HIV alone [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/117\" class=\"abstract_t\">117</a>]. In addition, two observational studies have suggested that discordance between absolute CD4 cell counts and CD4 T-cell percentages may be seen in patients with advanced liver disease, which may be related to splenic sequestration [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/136,137\" class=\"abstract_t\">136,137</a>]. (See <a href=\"#H15\" class=\"local\">'HIV-associated immune activation'</a> above and <a href=\"topic.htm?path=techniques-and-interpretation-of-measurement-of-the-cd4-cell-count-in-hiv-infected-patients\" class=\"medical medical_review\">&quot;Techniques and interpretation of measurement of the CD4 cell count in HIV-infected patients&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3616073095\"><span class=\"h2\">Other comorbidities</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Those with <span class=\"nowrap\">HCV/HIV</span> coinfection may experience greater rates of nonhepatic complications compared with HIV-infected patients who are HCV uninfected. Such complications include osteoporosis or bone fractures [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/138,139\" class=\"abstract_t\">138,139</a>] and chronic kidney disease [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/138-141\" class=\"abstract_t\">138-141</a>]. Whether HCV confers additional cardiovascular risk or is associated with neurocognitive decline in HIV-infected patients remains unclear [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/142-146\" class=\"abstract_t\">142-146</a>]. (See <a href=\"topic.htm?path=bone-and-calcium-disorders-in-hiv-infected-patients#H36156172\" class=\"medical medical_review\">&quot;Bone and calcium disorders in HIV-infected patients&quot;, section on 'Hepatitis C infection'</a> and <a href=\"topic.htm?path=overview-of-kidney-disease-in-hiv-positive-patients#H31719936\" class=\"medical medical_review\">&quot;Overview of kidney disease in HIV-positive patients&quot;, section on 'Glomerulonephritis due to hepatitis C virus co-infection'</a> and <a href=\"topic.htm?path=epidemiology-of-cardiovascular-disease-and-risk-factors-in-hiv-infected-patients#H2959230\" class=\"medical medical_review\">&quot;Epidemiology of cardiovascular disease and risk factors in HIV-infected patients&quot;, section on 'Hepatitis C virus infection'</a> and <a href=\"topic.htm?path=hiv-associated-neurocognitive-disorders-epidemiology-clinical-manifestations-and-diagnosis#H261704796\" class=\"medical medical_review\">&quot;HIV-associated neurocognitive disorders: Epidemiology, clinical manifestations, and diagnosis&quot;, section on 'Comorbidities'</a>.) </p><p class=\"headingAnchor\" id=\"H28\"><span class=\"h1\">SCREENING FOR HCV INFECTION</span></p><p class=\"headingAnchor\" id=\"H29\"><span class=\"h2\">Chronic infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>All HIV-infected persons should be screened for HCV infection using enzyme immunoassays; those with antibody to HCV should have quantitative HCV RNA testing, which confirms the presence of viremia and serves as a baseline prior to therapy [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/147\" class=\"abstract_t\">147</a>]. These recommendations also apply to patients with persistently normal aminotransferases, since patients can have advanced fibrosis despite these laboratory findings [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/148\" class=\"abstract_t\">148</a>]. (See <a href=\"topic.htm?path=screening-for-chronic-hepatitis-c-virus-infection\" class=\"medical medical_review\">&quot;Screening for chronic hepatitis C virus infection&quot;</a> and <a href=\"topic.htm?path=diagnosis-and-evaluation-of-chronic-hepatitis-c-virus-infection\" class=\"medical medical_review\">&quot;Diagnosis and evaluation of chronic hepatitis C virus infection&quot;</a>.)</p><p>The sensitivity and specificity of third generation ELISA assays approach 99 percent [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/147\" class=\"abstract_t\">147</a>]. However, patients with severe immunosuppression (eg, CD4 cell counts &lt;100 <span class=\"nowrap\">cells/microL)</span> may have a false negative serology due to impaired antibody formation; however, this occurs in than less than 5 percent of patients [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/149,150\" class=\"abstract_t\">149,150</a>]. Thus, any HCV-seronegative HIV-infected patient who has significant risk factors for HCV acquisition (eg, injection drug use), or has unexplained abnormal aminotransferases should be screened further with hepatitis C RNA testing [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/151\" class=\"abstract_t\">151</a>].</p><p>Patients with HIV infection are more likely to have HCV viremia compared with those without HIV infection. In two studies, for example, 91 percent of coinfected patients had HCV viremia compared with approximately 75 percent of those with HCV alone. A possible explanation is that clearance of HCV is less likely to occur in patients with underlying HIV [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/7,152\" class=\"abstract_t\">7,152</a>].</p><p class=\"headingAnchor\" id=\"H30\"><span class=\"h2\">Acute HCV infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In patients with suspected acute HCV infection, an HCV antibody and HCV RNA level should both be obtained since viremia precedes seroconversion. HCV antibody is detected approximately 8 to 12 weeks after infection although delayed antibody responses have been described in one small study of 43 HIV-infected patients [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/153,154\" class=\"abstract_t\">153,154</a>]. Yearly antibody screening of sexually-active HIV-infected patients is an additional strategy to capture incident cases [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/155,156\" class=\"abstract_t\">155,156</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-treatment-of-acute-hepatitis-c-virus-infection-in-adults\" class=\"medical medical_review\">&quot;Clinical manifestations, diagnosis, and treatment of acute hepatitis C virus infection in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H31\"><span class=\"h2\">Screening for other hepatitis viruses</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>All HIV-infected patients should also be screened for past exposure to other hepatitis viruses (eg, hepatitis A IgG antibody and hepatitis B surface antigen and surface antibody). Immunizations for hepatitis A and hepatitis B are recommended if the patient is not immune [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/157-159\" class=\"abstract_t\">157-159</a>]. (See <a href=\"topic.htm?path=prevention-of-hepatitis-b-virus-infection-in-the-hiv-infected-adult\" class=\"medical medical_review\">&quot;Prevention of hepatitis B virus infection in the HIV-infected adult&quot;</a> and <a href=\"topic.htm?path=immunizations-in-hiv-infected-patients#H3483023343\" class=\"medical medical_review\">&quot;Immunizations in HIV-infected patients&quot;, section on 'Hepatitis A vaccine'</a>.)</p><p class=\"headingAnchor\" id=\"H32\"><span class=\"h1\">HCV AND RISK OF HEPATOTOXICITY WITH ART</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Chronic viral hepatitis increases the risk of hepatotoxicity from antiretroviral therapy [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/160-169\" class=\"abstract_t\">160-169</a>]. Some have suggested that hepatitis C is associated with an increased risk of hepatotoxicity for all ART regimens [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/170,171\" class=\"abstract_t\">170,171</a>], while others found an increased risk only with certain antiretroviral agents, such as <a href=\"topic.htm?path=ritonavir-drug-information\" class=\"drug drug_general\">ritonavir</a> or <a href=\"topic.htm?path=nevirapine-drug-information\" class=\"drug drug_general\">nevirapine</a> [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/160,161,172\" class=\"abstract_t\">160,161,172</a>].</p><p>Although hepatotoxicity is more common in patients with chronic viral hepatitis, the clear benefit of antiretroviral therapy outweighs the risk of liver injury. Studies also support the positive impact of antiretroviral treatment on the progression of hepatic fibrosis in <span class=\"nowrap\">HIV/HCV-coinfected</span> patients [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/113\" class=\"abstract_t\">113</a>]. (See <a href=\"#H46115450\" class=\"local\">'Effect of ART on HCV progression'</a> above.)</p><p>When patients with concomitant HCV are initiated on ART, close laboratory follow-up is prudent and patients should be educated about symptoms that may suggest liver injury such as jaundice or darkening of urine, right upper quadrant pain, nausea, anorexia, pruritus and fatigue.</p><p>The pathogenesis of ART-associated hepatotoxicity may be related to immune reconstitution, which leads to hepatocyte necrosis [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/168\" class=\"abstract_t\">168</a>]. Supporting this hypothesis is the observation that hepatotoxicity correlated with a rise in CD4 count in some reports [<a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/167,168\" class=\"abstract_t\">167,168</a>]. However, an increase in the CD4 count may simply be a marker of a patient who is adherent with their medications and therefore at higher risk of drug injury compared with the patient who is not taking their medications at all.</p><p>The evaluation and treatment of hepatitis C in the HIV-infected patient is discussed separately. (See <a href=\"topic.htm?path=evaluation-of-the-hiv-infected-patient-with-chronic-hepatitis-c-virus-infection\" class=\"medical medical_review\">&quot;Evaluation of the HIV-infected patient with chronic hepatitis C virus infection&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1147018587\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-hepatitis-c-virus-infection\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Hepatitis C virus infection&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H33\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>During the chronic stage of both HIV and HCV, a relatively stable viral load or &quot;set point&quot; is maintained over long periods of time. However, in the setting of HIV, HCV RNA levels increase after HIV seroconversion and continue to increase over time. (See <a href=\"#H2\" class=\"local\">'Virology of HCV'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Coinfection with HIV and HCV is common since both infections share similar routes of transmission. Prevalence rates vary by primary route of transmission. (See <a href=\"#H7\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><span class=\"nowrap\">HIV/HCV-coinfected</span> patients have accelerated rates of fibrosis progression compared with patients with HCV alone, which may be related to HIV-associated immune activation, CD4 T cell depletion or immunodysregulation with production of proinflammatory cytokines. (See <a href=\"#H13\" class=\"local\">'Pathogenesis of liver disease'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients with chronic HCV infection, concomitant HIV infection is associated with higher rates of morbidity and mortality related to end-stage liver disease. (See <a href=\"#H19\" class=\"local\">'Effect of HIV on the natural history of HCV'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>There are conflicting studies as to whether HCV affects the clinical progression of HIV disease. (See <a href=\"#H27\" class=\"local\">'Effect of HCV on the natural history of HIV'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>All HIV-infected persons should be evaluated for chronic HCV infection using a third generation enzyme immunoassay. Patients who are found to be HCV seropositive should undergo quantitative HCV RNA testing in order to confirm the presence of viremia. Patients who are found to be HCV seronegative should undergo HCV RNA testing if they have advanced immunosuppression (eg, CD4 counts &lt;100 <span class=\"nowrap\">cells/mm3),</span> risk factors for HCV infection, or elevated aminotransferases. (See <a href=\"#H28\" class=\"local\">'Screening for HCV infection'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Chronic viral hepatitis increases the risk of hepatotoxicity from antiretroviral therapy. Patients should be counseled regarding the symptoms and signs of drug-induced liver injury prior to starting antiretroviral therapy. (See <a href=\"#H32\" class=\"local\">'HCV and risk of hepatotoxicity with ART'</a> above.)</p><p/><p><strong>ACKNOWLEDGMENT</strong> &mdash; The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Barbara McGovern, who contributed to an earlier version of this topic review.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/1\" class=\"nounderline abstract_t\">McGovern BH. Hepatitis C in the HIV-infected patient. J Acquir Immune Defic Syndr 2007; 45 Suppl 2:S47.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/2\" class=\"nounderline abstract_t\">Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373:123.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/3\" class=\"nounderline abstract_t\">Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282:103.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/4\" class=\"nounderline abstract_t\">Piatak M Jr, Saag MS, Yang LC, et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993; 259:1749.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/5\" class=\"nounderline abstract_t\">Nguyen TT, Sedghi-Vaziri A, Wilkes LB, et al. Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection. J Viral Hepat 1996; 3:75.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/6\" class=\"nounderline abstract_t\">Thomas DL, Shih JW, Alter HJ, et al. Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J Infect Dis 1996; 174:690.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/7\" class=\"nounderline abstract_t\">Daar ES, Lynn H, Donfield S, et al. Relation between HIV-1 and hepatitis C viral load in patients with hemophilia. J Acquir Immune Defic Syndr 2001; 26:466.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/8\" class=\"nounderline abstract_t\">Barreiro P, Labarga P, de Mendoza C, et al. High serum HCV RNA in chronic hepatitis C patients coinfected with HIV despite successful antiretroviral therapy. Antivir Ther 2016; 21:489.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/9\" class=\"nounderline abstract_t\">Ghany MG, Leissinger C, Lagier R, et al. Effect of human immunodeficiency virus infection on hepatitis C virus infection in hemophiliacs. Dig Dis Sci 1996; 41:1265.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/10\" class=\"nounderline abstract_t\">Cooper CL, Cameron DW. Effect of alcohol use and highly active antiretroviral therapy on plasma levels of hepatitis C virus (HCV) in patients coinfected with HIV and HCV. Clin Infect Dis 2005; 41 Suppl 1:S105.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/11\" class=\"nounderline abstract_t\">Netski DM, Mao Q, Ray SC, Klein RS. Genetic divergence of hepatitis C virus: the role of HIV-related immunosuppression. J Acquir Immune Defic Syndr 2008; 49:136.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/12\" class=\"nounderline abstract_t\">Lin W, Weinberg EM, Tai AW, et al. HIV increases HCV replication in a TGF-beta1-dependent manner. Gastroenterology 2008; 134:803.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/13\" class=\"nounderline abstract_t\">Goutagny N, Fatmi A, De Ledinghen V, et al. Evidence of viral replication in circulating dendritic cells during hepatitis C virus infection. J Infect Dis 2003; 187:1951.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/14\" class=\"nounderline abstract_t\">Blackard JT, Kemmer N, Sherman KE. Extrahepatic replication of HCV: insights into clinical manifestations and biological consequences. Hepatology 2006; 44:15.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/15\" class=\"nounderline abstract_t\">Lanford RE, Chavez D, Chisari FV, Sureau C. Lack of detection of negative-strand hepatitis C virus RNA in peripheral blood mononuclear cells and other extrahepatic tissues by the highly strand-specific rTth reverse transcriptase PCR. J Virol 1995; 69:8079.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/16\" class=\"nounderline abstract_t\">Blackard JT, Smeaton L, Hiasa Y, et al. Detection of hepatitis C virus (HCV) in serum and peripheral-blood mononuclear cells from HCV-monoinfected and HIV/HCV-coinfected persons. J Infect Dis 2005; 192:258.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/17\" class=\"nounderline abstract_t\">Laskus T, Radkowski M, Piasek A, et al. Hepatitis C virus in lymphoid cells of patients coinfected with human immunodeficiency virus type 1: evidence of active replication in monocytes/macrophages and lymphocytes. J Infect Dis 2000; 181:442.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/18\" class=\"nounderline abstract_t\">Goletti D, Weissman D, Jackson RW, et al. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol 1996; 157:1271.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/19\" class=\"nounderline abstract_t\">Graham CS, Koziel MJ. Why should hepatitis C affect immune reconstitution in HIV-1-infected patients? Lancet 2000; 356:1865.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/20\" class=\"nounderline abstract_t\">Minosse C, Calcaterra S, Abbate I, et al. Possible compartmentalization of hepatitis C viral replication in the genital tract of HIV-1-coinfected women. J Infect Dis 2006; 194:1529.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/21\" class=\"nounderline abstract_t\">Nowicki MJ, Laskus T, Nikolopoulou G, et al. Presence of hepatitis C virus (HCV) RNA in the genital tracts of HCV/HIV-1-coinfected women. J Infect Dis 2005; 192:1557.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/22\" class=\"nounderline abstract_t\">Holland JJ, De La Torre JC, Steinhauer DA. RNA virus populations as quasispecies. Curr Top Microbiol Immunol 1992; 176:1.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/23\" class=\"nounderline abstract_t\">Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995; 267:483.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/24\" class=\"nounderline abstract_t\">Havlir DV, Richman DD. Viral dynamics of HIV: implications for drug development and therapeutic strategies. Ann Intern Med 1996; 124:984.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/25\" class=\"nounderline abstract_t\">Davis GL. Hepatitis C virus genotypes and quasispecies. Am J Med 1999; 107:21S.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/26\" class=\"nounderline abstract_t\">Sherman KE, Andreatta C, O'Brien J, et al. Hepatitis C in human immunodeficiency virus-coinfected patients: increased variability in the hypervariable envelope coding domain. Hepatology 1996; 23:688.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/27\" class=\"nounderline abstract_t\">Speck RF, Wehrly K, Platt EJ, et al. Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop. J Virol 1997; 71:7136.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/28\" class=\"nounderline abstract_t\">Toyoda H, Kumada T, Nakano S, et al. Quasispecies nature of hepatitis C virus and response to alpha interferon: significance as a predictor of direct response to interferon. J Hepatol 1997; 26:6.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/29\" class=\"nounderline abstract_t\">Sherman KE, Rouster SD, Stanford S, et al. Hepatitis C virus (HCV) quasispecies complexity and selection in HCV/HIV-coinfected subjects treated with interferon-based regimens. J Infect Dis 2010; 201:712.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/30\" class=\"nounderline abstract_t\">Blackard JT, Hiasa Y, Smeaton L, et al. Compartmentalization of hepatitis C virus (HCV) during HCV/HIV coinfection. J Infect Dis 2007; 195:1765.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/31\" class=\"nounderline abstract_t\">McGovern BH, Abu Dayyeh BK, Chung RT. Avoiding therapeutic pitfalls: the rational use of specifically targeted agents against hepatitis C infection. Hepatology 2008; 48:1700.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/32\" class=\"nounderline abstract_t\">Kuntzen T, Timm J, Berical A, et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-na&iuml;ve patients. Hepatology 2008; 48:1769.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/33\" class=\"nounderline abstract_t\">Gaudieri S, Rauch A, Pfafferott K, et al. Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology 2009; 49:1069.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/34\" class=\"nounderline abstract_t\">Platt L, Easterbrook P, Gower E, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis 2016; 16:797.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/35\" class=\"nounderline abstract_t\">Staples CT Jr, Rimland D, Dudas D. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival. Clin Infect Dis 1999; 29:150.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/36\" class=\"nounderline abstract_t\">Berenguer J, Rivero A, Jarr&iacute;n I, et al. Human Immunodeficiency Virus/Hepatitis C Virus Coinfection in Spain: Prevalence and Patient Characteristics. Open Forum Infect Dis 2016; 3:ofw059.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/37\" class=\"nounderline abstract_t\">Garfein RS, Vlahov D, Galai N, et al. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996; 86:655.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/38\" class=\"nounderline abstract_t\">Kim AY, Chung RT. Coinfection with HIV-1 and HCV--a one-two punch. Gastroenterology 2009; 137:795.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/39\" class=\"nounderline abstract_t\">Alter MJ, Hadler SC, Judson FN, et al. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. JAMA 1990; 264:2231.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/40\" class=\"nounderline abstract_t\">Conrad C, Bradley HM, Broz D, et al. Community Outbreak of HIV Infection Linked to Injection Drug Use of Oxymorphone--Indiana, 2015. MMWR Morb Mortal Wkly Rep 2015; 64:443.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/41\" class=\"nounderline abstract_t\">Thomas DL, Zenilman JM, Alter HJ, et al. Sexual transmission of hepatitis C virus among patients attending sexually transmitted diseases clinics in Baltimore--an analysis of 309 sex partnerships. J Infect Dis 1995; 171:768.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/42\" class=\"nounderline abstract_t\">Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/43\" class=\"nounderline abstract_t\">Osmond DH, Padian NS, Sheppard HW, et al. Risk factors for hepatitis C virus seropositivity in heterosexual couples. JAMA 1993; 269:361.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/44\" class=\"nounderline abstract_t\">Tohme RA, Holmberg SD. Is sexual contact a major mode of hepatitis C virus transmission? Hepatology 2010; 52:1497.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/45\" class=\"nounderline abstract_t\">Eyster ME, Alter HJ, Aledort LM, et al. Heterosexual co-transmission of hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Ann Intern Med 1991; 115:764.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/46\" class=\"nounderline abstract_t\">Soto B, Rodrigo L, Garcia-Bengoechea M, et al. Heterosexual transmission of hepatitis C virus and the possible role of coexistent human immunodeficiency virus infection in the index case. A multicentre study of 423 pairings. J Intern Med 1994; 236:515.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/47\" class=\"nounderline abstract_t\">Wyld R, Robertson JR, Brettle RP, et al. Absence of hepatitis C virus transmission but frequent transmission of HIV-1 from sexual contact with doubly-infected individuals. J Infect 1997; 35:163.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/48\" class=\"nounderline abstract_t\">Garg S, Taylor LE, Grasso C, Mayer KH. Prevalent and incident hepatitis C virus infection among HIV-infected men who have sex with men engaged in primary care in a Boston community health center. Clin Infect Dis 2013; 56:1480.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/49\" class=\"nounderline abstract_t\">Raymond HF, Hughes A, O'Keefe K, et al. Hepatitis C prevalence among HIV-positive MSM in San Francisco: 2004 and 2008. Sex Transm Dis 2011; 38:219.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/50\" class=\"nounderline abstract_t\">Osmond DH, Charlebois E, Sheppard HW, et al. Comparison of risk factors for hepatitis C and hepatitis B virus infection in homosexual men. J Infect Dis 1993; 167:66.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/51\" class=\"nounderline abstract_t\">Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341:556.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/52\" class=\"nounderline abstract_t\">Urbanus AT, van de Laar TJ, Stolte IG, et al. Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic. AIDS 2009; 23:F1.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/53\" class=\"nounderline abstract_t\">Wandeler G, Gsponer T, Bregenzer A, et al. Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic. Clin Infect Dis 2012; 55:1408.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/54\" class=\"nounderline abstract_t\">Luetkemeyer A, Hare CB, Stansell J, et al. Clinical presentation and course of acute hepatitis C infection in HIV-infected patients. J Acquir Immune Defic Syndr 2006; 41:31.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/55\" class=\"nounderline abstract_t\">van de Laar TJ, van der Bij AK, Prins M, et al. Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. J Infect Dis 2007; 196:230.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/56\" class=\"nounderline abstract_t\">Rauch A, Rickenbach M, Weber R, et al. Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study. Clin Infect Dis 2005; 41:395.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/57\" class=\"nounderline abstract_t\">Fierer DS, Uriel AJ, Carriero DC, et al. Liver fibrosis during an outbreak of acute hepatitis C virus infection in HIV-infected men: a prospective cohort study. J Infect Dis 2008; 198:683.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/58\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Sexual transmission of hepatitis C virus among HIV-infected men who have sex with men--New York City, 2005-2010. MMWR Morb Mortal Wkly Rep 2011; 60:945.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/59\" class=\"nounderline abstract_t\">Serpaggi J, Chaix ML, Batisse D, et al. Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy. AIDS 2006; 20:233.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/60\" class=\"nounderline abstract_t\">Danta M, Brown D, Bhagani S, et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS 2007; 21:983.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/61\" class=\"nounderline abstract_t\">G&ouml;tz HM, van Doornum G, Niesters HG, et al. A cluster of acute hepatitis C virus infection among men who have sex with men--results from contact tracing and public health implications. AIDS 2005; 19:969.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/62\" class=\"nounderline abstract_t\">Vanhommerig JW, Lambers FA, Schinkel J, et al. Risk Factors for Sexual Transmission of Hepatitis C Virus Among Human Immunodeficiency Virus-Infected Men Who Have Sex With Men: A Case-Control Study. Open Forum Infect Dis 2015; 2:ofv115.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/63\" class=\"nounderline abstract_t\">Witt MD, Seaberg EC, Darilay A, et al. Incident hepatitis C virus infection in men who have sex with men: a prospective cohort analysis, 1984-2011. Clin Infect Dis 2013; 57:77.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/64\" class=\"nounderline abstract_t\">Polis CB, Shah SN, Johnson KE, Gupta A. Impact of maternal HIV coinfection on the vertical transmission of hepatitis C virus: a meta-analysis. Clin Infect Dis 2007; 44:1123.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/65\" class=\"nounderline abstract_t\">Ridzon R, Gallagher K, Ciesielski C, et al. Simultaneous transmission of human immunodeficiency virus and hepatitis C virus from a needle-stick injury. N Engl J Med 1997; 336:919.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/66\" class=\"nounderline abstract_t\">Yonkers NL, Rodriguez B, Post AB, et al. HIV coinfection impairs CD28-mediated costimulation of hepatitis C virus-specific CD8 cells. J Infect Dis 2006; 194:391.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/67\" class=\"nounderline abstract_t\">Kim AY, Lauer GM, Ouchi K, et al. The magnitude and breadth of hepatitis C virus-specific CD8+ T cells depend on absolute CD4+ T-cell count in individuals coinfected with HIV-1. Blood 2005; 105:1170.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/68\" class=\"nounderline abstract_t\">Rohrbach J, Robinson N, Harcourt G, et al. Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy. Gut 2010; 59:1252.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/69\" class=\"nounderline abstract_t\">Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/70\" class=\"nounderline abstract_t\">Balagopal A, Philp FH, Astemborski J, et al. Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology 2008; 135:226.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/71\" class=\"nounderline abstract_t\">Balagopal A, Ray SC, De Oca RM, et al. Kupffer cells are depleted with HIV immunodeficiency and partially recovered with antiretroviral immune reconstitution. AIDS 2009; 23:2397.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/72\" class=\"nounderline abstract_t\">Allison RD, Katsounas A, Koziol DE, et al. Association of interleukin-15-induced peripheral immune activation with hepatic stellate cell activation in persons coinfected with hepatitis C virus and HIV. J Infect Dis 2009; 200:619.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/73\" class=\"nounderline abstract_t\">Volkmann X, Fischer U, Bahr MJ, et al. Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver. Hepatology 2007; 46:1498.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/74\" class=\"nounderline abstract_t\">Babu CK, Suwansrinon K, Bren GD, et al. HIV induces TRAIL sensitivity in hepatocytes. PLoS One 2009; 4:e4623.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/75\" class=\"nounderline abstract_t\">Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32:492.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/76\" class=\"nounderline abstract_t\">Weber R, Sabin CA, Friis-M&oslash;ller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166:1632.</a></li><li class=\"breakAll\">Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf (Accessed on July 10, 2017).</li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/78\" class=\"nounderline abstract_t\">Berenguer J, Rodr&iacute;guez E, Miralles P, et al. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus. Clin Infect Dis 2012; 55:728.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/79\" class=\"nounderline abstract_t\">Danta M, Semmo N, Fabris P, et al. Impact of HIV on host-virus interactions during early hepatitis C virus infection. J Infect Dis 2008; 197:1558.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/80\" class=\"nounderline abstract_t\">Kim AY, Schulze zur Wiesch J, Kuntzen T, et al. Impaired hepatitis C virus-specific T cell responses and recurrent hepatitis C virus in HIV coinfection. PLoS Med 2006; 3:e492.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/81\" class=\"nounderline abstract_t\">Thomson EC, Fleming VM, Main J, et al. Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men. Gut 2011; 60:837.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/82\" class=\"nounderline abstract_t\">Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30:1054.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/83\" class=\"nounderline abstract_t\">Monga HK, Rodriguez-Barradas MC, Breaux K, et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 33:240.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/84\" class=\"nounderline abstract_t\">Kirk GD, Mehta SH, Astemborski J, et al. HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study. Ann Intern Med 2013; 158:658.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/85\" class=\"nounderline abstract_t\">Fierer DS, Dieterich DT, Fiel MI, et al. Rapid progression to decompensated cirrhosis, liver transplant, and death in HIV-infected men after primary hepatitis C virus infection. Clin Infect Dis 2013; 56:1038.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/86\" class=\"nounderline abstract_t\">Konerman MA, Mehta SH, Sutcliffe CG, et al. Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: prospective analysis of 435 liver biopsy pairs. Hepatology 2014; 59:767.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/87\" class=\"nounderline abstract_t\">Sulkowski MS, Mehta SH, Torbenson MS, et al. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS 2007; 21:2209.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/88\" class=\"nounderline abstract_t\">Mac&iacute;as J, Berenguer J, Jap&oacute;n MA, et al. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology 2009; 50:1056.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/89\" class=\"nounderline abstract_t\">Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33:562.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/90\" class=\"nounderline abstract_t\">Sterling RK, Contos MJ, Sanyal AJ, et al. The clinical spectrum of hepatitis C virus in HIV coinfection. J Acquir Immune Defic Syndr 2003; 32:30.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/91\" class=\"nounderline abstract_t\">Martinez-Sierra C, Arizcorreta A, D&iacute;az F, et al. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis 2003; 36:491.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/92\" class=\"nounderline abstract_t\">McGovern BH, Ditelberg JS, Taylor LE, et al. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin Infect Dis 2006; 43:365.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/93\" class=\"nounderline abstract_t\">Gaslightwala I, Bini EJ. Impact of human immunodeficiency virus infection on the prevalence and severity of steatosis in patients with chronic hepatitis C virus infection. J Hepatol 2006; 44:1026.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/94\" class=\"nounderline abstract_t\">Sterling RK, Contos MJ, Smith PG, et al. Steatohepatitis: Risk factors and impact on disease severity in human immunodeficiency virus/hepatitis C virus coinfection. Hepatology 2008; 47:1118.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/95\" class=\"nounderline abstract_t\">Mac&iacute;as J, Berenguer J, Jap&oacute;n MA, et al. Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus-coinfected patients. Hepatology 2012; 56:1261.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/96\" class=\"nounderline abstract_t\">Kim HN, Nance R, Van Rompaey S, et al. Poorly Controlled HIV Infection: An Independent Risk Factor for Liver Fibrosis. J Acquir Immune Defic Syndr 2016; 72:437.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/97\" class=\"nounderline abstract_t\">Limketkai BN, Mehta SH, Sutcliffe CG, et al. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA 2012; 308:370.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/98\" class=\"nounderline abstract_t\">Mac&iacute;as J, M&aacute;rquez M, T&eacute;llez F, et al. Risk of liver decompensation among HIV/hepatitis C virus-coinfected individuals with advanced fibrosis: implications for the timing of therapy. Clin Infect Dis 2013; 57:1401.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/99\" class=\"nounderline abstract_t\">Salmon-Ceron D, Rosenthal E, Lewden C, et al. Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: The French national Mortalit&eacute; 2005 study. J Hepatol 2009; 50:736.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/100\" class=\"nounderline abstract_t\">Merchante N, Merino E, L&oacute;pez-Aldeguer J, et al. Increasing incidence of hepatocellular carcinoma in HIV-infected patients in Spain. Clin Infect Dis 2013; 56:143.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/101\" class=\"nounderline abstract_t\">Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008; 148:728.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/102\" class=\"nounderline abstract_t\">Puoti M, Bruno R, Soriano V, et al. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS 2004; 18:2285.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/103\" class=\"nounderline abstract_t\">Kramer JR, Kowalkowski MA, Duan Z, Chiao EY. The effect of HIV viral control on the incidence of hepatocellular carcinoma in veterans with hepatitis C and HIV coinfection. J Acquir Immune Defic Syndr 2015; 68:456.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/104\" class=\"nounderline abstract_t\">Br&auml;u N, Fox RK, Xiao P, et al. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol 2007; 47:527.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/105\" class=\"nounderline abstract_t\">Lo Re V 3rd, Kallan MJ, Tate JP, et al. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Ann Intern Med 2014; 160:369.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/106\" class=\"nounderline abstract_t\">Anderson JP, Tchetgen Tchetgen EJ, Lo Re V 3rd, et al. Antiretroviral therapy reduces the rate of hepatic decompensation among HIV- and hepatitis C virus-coinfected veterans. Clin Infect Dis 2014; 58:719.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/107\" class=\"nounderline abstract_t\">Pineda JA, Garc&iacute;a-Garc&iacute;a JA, Aguilar-Guisado M, et al. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology 2007; 46:622.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/108\" class=\"nounderline abstract_t\">Pineda JA, Aguilar-Guisado M, Rivero A, et al. Natural history of compensated hepatitis C virus-related cirrhosis in HIV-infected patients. Clin Infect Dis 2009; 49:1274.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/109\" class=\"nounderline abstract_t\">Lo Re V 3rd, Wang L, Devine S, et al. Hepatic decompensation in patients with HIV/Hepatitis B Virus (HBV)/Hepatitis C Virus (HCV) triple infection versus HIV/HCV coinfection and the effect of anti-HBV nucleos(t)ide therapy. Clin Infect Dis 2014; 59:1027.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/110\" class=\"nounderline abstract_t\">Lohse N, Hansen AB, Pedersen G, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007; 146:87.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/111\" class=\"nounderline abstract_t\">Chen TY, Ding EL, Seage Iii GR, Kim AY. Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin Infect Dis 2009; 49:1605.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/112\" class=\"nounderline abstract_t\">Merchante N, Gir&oacute;n-Gonz&aacute;lez JA, Gonz&aacute;lez-Serrano M, et al. Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. AIDS 2006; 20:49.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/113\" class=\"nounderline abstract_t\">Br&auml;u N, Salvatore M, R&iacute;os-Bedoya CF, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006; 44:47.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/114\" class=\"nounderline abstract_t\">Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 2008; 22:1979.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/115\" class=\"nounderline abstract_t\">Klein MB, Althoff KN, Jing Y, et al. Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras. Clin Infect Dis 2016; 63:1160.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/116\" class=\"nounderline abstract_t\">Anderson KB, Guest JL, Rimland D. Hepatitis C virus coinfection increases mortality in HIV-infected patients in the highly active antiretroviral therapy era: data from the HIV Atlanta VA Cohort Study. Clin Infect Dis 2004; 39:1507.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/117\" class=\"nounderline abstract_t\">Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356:1800.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/118\" class=\"nounderline abstract_t\">Pascual-Pareja JF, Caminoa A, Larrauri C, et al. HAART is associated with lower hepatic necroinflammatory activity in HIV-hepatitis C virus-coinfected patients with CD4 cell count of more than 350 cells/microl at the time of liver biopsy. AIDS 2009; 23:971.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/119\" class=\"nounderline abstract_t\">Thorpe J, Saeed S, Moodie EE, et al. Antiretroviral treatment interruption leads to progression of liver fibrosis in HIV-hepatitis C virus co-infection. AIDS 2011; 25:967.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/120\" class=\"nounderline abstract_t\">Shafran SD. Early initiation of antiretroviral therapy: the current best way to reduce liver-related deaths in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2007; 44:551.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/121\" class=\"nounderline abstract_t\">Berenguer J, Bell&oacute;n JM, Miralles P, et al. Association between exposure to nevirapine and reduced liver fibrosis progression in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2008; 46:137.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/122\" class=\"nounderline abstract_t\">Mac&iacute;as J, Castellano V, Merchante N, et al. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. AIDS 2004; 18:767.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/123\" class=\"nounderline abstract_t\">Yoo TW, Donfield S, Lail A, et al. Effect of hepatitis C virus (HCV) genotype on HCV and HIV-1 disease. J Infect Dis 2005; 191:4.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/124\" class=\"nounderline abstract_t\">Daar ES, Lynn H, Donfield S, et al. Hepatitis C virus load is associated with human immunodeficiency virus type 1 disease progression in hemophiliacs. J Infect Dis 2001; 183:589.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/125\" class=\"nounderline abstract_t\">Tedaldi EM, Baker RK, Moorman AC, et al. Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2003; 36:363.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/126\" class=\"nounderline abstract_t\">Hernando V, Perez-Cachafeiro S, Lewden C, et al. All-cause and liver-related mortality in HIV positive subjects compared to the general population: differences by HCV co-infection. J Hepatol 2012; 57:743.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/127\" class=\"nounderline abstract_t\">Sulkowski MS, Moore RD, Mehta SH, et al. Hepatitis C and progression of HIV disease. JAMA 2002; 288:199.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/128\" class=\"nounderline abstract_t\">Rockstroh JK, Mocroft A, Soriano V, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005; 192:992.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/129\" class=\"nounderline abstract_t\">Piroth L. Coinfection with hepatitis C virus and HIV: more than double trouble. Clin Infect Dis 2009; 49:623.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/130\" class=\"nounderline abstract_t\">van der Helm J, Geskus R, Sabin C, et al. Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997. Gastroenterology 2013; 144:751.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/131\" class=\"nounderline abstract_t\">Sherman KE, O'Brien J, Gutierrez AG, et al. Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infections. J Clin Microbiol 1993; 31:2679.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/132\" class=\"nounderline abstract_t\">Dorrucci M, Pezzotti P, Phillips AN, et al. Coinfection of hepatitis C virus with human immunodeficiency virus and progression to AIDS. Italian Seroconversion Study. J Infect Dis 1995; 172:1503.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/133\" class=\"nounderline abstract_t\">Kovacs A, Karim R, Mack WJ, et al. Activation of CD8 T cells predicts progression of HIV infection in women coinfected with hepatitis C virus. J Infect Dis 2010; 201:823.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/134\" class=\"nounderline abstract_t\">Giorgi JV, Hultin LE, McKeating JA, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999; 179:859.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/135\" class=\"nounderline abstract_t\">Potter M, Odueyungbo A, Yang H, et al. Impact of hepatitis C viral replication on CD4+ T-lymphocyte progression in HIV-HCV coinfection before and after antiretroviral therapy. AIDS 2010; 24:1857.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/136\" class=\"nounderline abstract_t\">Hull MW, Rollet K, Odueyungbo A, et al. Factors associated with discordance between absolute CD4 cell count and CD4 cell percentage in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis 2012; 54:1798.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/137\" class=\"nounderline abstract_t\">Claassen CW, Diener-West M, Mehta SH, et al. Discordance between CD4+ T-lymphocyte counts and percentages in HIV-infected persons with liver fibrosis. Clin Infect Dis 2012; 54:1806.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/138\" class=\"nounderline abstract_t\">Dong HV, Cort&eacute;s YI, Shiau S, Yin MT. Osteoporosis and fractures in HIV/hepatitis C virus coinfection: a systematic review and meta-analysis. AIDS 2014; 28:2119.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/139\" class=\"nounderline abstract_t\">O'Neill TJ, Rivera L, Struchkov V, et al. The effect of HIV-hepatitis C co-infection on bone mineral density and fracture: a meta-analysis. PLoS One 2014; 9:e101493.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/140\" class=\"nounderline abstract_t\">Lucas GM, Jing Y, Sulkowski M, et al. Hepatitis C viremia and the risk of chronic kidney disease in HIV-infected individuals. J Infect Dis 2013; 208:1240.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/141\" class=\"nounderline abstract_t\">Kovari H, Rauch A, Kouyos R, et al. Hepatitis C Infection and the Risk of Non-Liver-Related Morbidity and Mortality in HIV-Infected Persons in the Swiss HIV Cohort Study. Clin Infect Dis 2017; 64:490.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/142\" class=\"nounderline abstract_t\">Kakinami L, Block RC, Adams MJ, et al. Risk of cardiovascular disease in HIV, hepatitis C, or HIV/hepatitis C patients compared to the general population. Int J Clin Pract 2013; 67:6.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/143\" class=\"nounderline abstract_t\">Sosner P, Wangermez M, Chagneau-Derrode C, et al. Atherosclerosis risk in HIV-infected patients: the influence of hepatitis C virus co-infection. Atherosclerosis 2012; 222:274.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/144\" class=\"nounderline abstract_t\">Masi&aacute; M, Padilla S, Robledano C, et al. Evaluation of endothelial function and subclinical atherosclerosis in association with hepatitis C virus in HIV-infected patients: a cross-sectional study. BMC Infect Dis 2011; 11:265.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/145\" class=\"nounderline abstract_t\">Freiberg MS, Chang CC, Skanderson M, et al. The risk of incident coronary heart disease among veterans with and without HIV and hepatitis C. Circ Cardiovasc Qual Outcomes 2011; 4:425.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/146\" class=\"nounderline abstract_t\">Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group, Weber R, Sabin C, et al. HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study. Antivir Ther 2010; 15:1077.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/147\" class=\"nounderline abstract_t\">Strader DB, Wright T, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39:1147.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/148\" class=\"nounderline abstract_t\">Bani-Sadr F, Barange K, Daoud F, et al. Persistently normal alanine aminotransferase levels in HIV/HCV-coinfected patients: the role of steatosis. HIV Med 2009; 10:417.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/149\" class=\"nounderline abstract_t\">Bonacini M, Lin HJ, Hollinger FB. Effect of coexisting HIV-1 infection on the diagnosis and evaluation of hepatitis C virus. J Acquir Immune Defic Syndr 2001; 26:340.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/150\" class=\"nounderline abstract_t\">Thio CL, Nolt KR, Astemborski J, et al. Screening for hepatitis C virus in human immunodeficiency virus-infected individuals. J Clin Microbiol 2000; 38:575.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/151\" class=\"nounderline abstract_t\">Chamie G, Bonacini M, Bangsberg DR, et al. Factors associated with seronegative chronic hepatitis C virus infection in HIV infection. Clin Infect Dis 2007; 44:577.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/152\" class=\"nounderline abstract_t\">Mehta SH, Cox A, Hoover DR, et al. Protection against persistence of hepatitis C. Lancet 2002; 359:1478.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/153\" class=\"nounderline abstract_t\">Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49:1335.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/154\" class=\"nounderline abstract_t\">Thomson EC, Nastouli E, Main J, et al. Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV. AIDS 2009; 23:89.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/155\" class=\"nounderline abstract_t\">Aberg JA, Gallant JE, Ghanem KG, et al. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2014; 58:1.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/156\" class=\"nounderline abstract_t\">Linas BP, Wong AY, Schackman BR, et al. Cost-effective screening for acute hepatitis C virus infection in HIV-infected men who have sex with men. Clin Infect Dis 2012; 55:279.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/157\" class=\"nounderline abstract_t\">Laurence JC. Hepatitis A and B immunizations of individuals infected with human immunodeficiency virus. Am J Med 2005; 118 Suppl 10A:75S.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/158\" class=\"nounderline abstract_t\">Nelson M, Matthews G, Brook MG, et al. BHIVA guidelines on HIV and chronic hepatitis: coinfection with HIV and hepatitis C virus infection (2005). HIV Med 2005; 6 Suppl 2:96.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/159\" class=\"nounderline abstract_t\">Alberti A, Clumeck N, Collins S, et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005; 42:615.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/160\" class=\"nounderline abstract_t\">Bonfanti P, Valsecchi L, Parazzini F, et al. Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group. J Acquir Immune Defic Syndr 2000; 23:236.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/161\" class=\"nounderline abstract_t\">Cooper CL, Parbhakar MA, Angel JB. Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis 2002; 34:1259.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/162\" class=\"nounderline abstract_t\">den Brinker M, Wit FW, Wertheim-van Dillen PM, et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000; 14:2895.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/163\" class=\"nounderline abstract_t\">N&uacute;&ntilde;ez M, Lana R, Mendoza JL, et al. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 27:426.</a></li><li class=\"breakAll\">Reisler R, Burman W, et al. Incidence of grade IV events, AIDS, and mortality in a large multicenter cohort receiving HAART, Abstract #36. In: 9th Conference on Retroviruses and Opportunistic Infections, Foundation for Retrovirology and Human Health, Seattle, WA 2002.</li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/165\" class=\"nounderline abstract_t\">Vento S, Garofano T, Renzini C, et al. Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combination therapy. AIDS 1998; 12:116.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/166\" class=\"nounderline abstract_t\">Puoti M, Torti C, Ripamonti D, et al. Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome. J Acquir Immune Defic Syndr 2003; 32:259.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/167\" class=\"nounderline abstract_t\">French AL, Benning L, Anastos K, et al. Longitudinal effect of antiretroviral therapy on markers of hepatic toxicity: impact of hepatitis C coinfection. Clin Infect Dis 2004; 39:402.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/168\" class=\"nounderline abstract_t\">Sav&egrave;s M, Vandentorren S, Daucourt V, et al. Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. Groupe dEpid&eacute;miologie Clinique de Sida en Aquitaine (GECSA). AIDS 1999; 13:F115.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/169\" class=\"nounderline abstract_t\">Servoss JC, Kitch DW, Andersen JW, et al. Predictors of antiretroviral-related hepatotoxicity in the adult AIDS Clinical Trial Group (1989-1999). J Acquir Immune Defic Syndr 2006; 43:320.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/170\" class=\"nounderline abstract_t\">Marin&eacute;-Barjoan E, Saint-Paul MC, Pradier C, et al. Impact of antiretroviral treatment on progression of hepatic fibrosis in HIV/hepatitis C virus co-infected patients. AIDS 2004; 18:2163.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/171\" class=\"nounderline abstract_t\">John M, Flexman J, French MA. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease? AIDS 1998; 12:2289.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-hepatitis-c-in-the-hiv-infected-patient/abstract/172\" class=\"nounderline abstract_t\">Vispo E, Fern&aacute;ndez-Montero JV, Labarga P, et al. Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV-hepatitis C virus coinfected patients. AIDS 2013; 27:1187.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 3712 Version 37.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H33\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">VIROLOGY OF HCV</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Viral kinetics</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">Viral load</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Viral reservoirs</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">Genetic heterogeneity</a></li></ul></li><li><a href=\"#H7\" id=\"outline-link-H7\">EPIDEMIOLOGY</a><ul><li><a href=\"#H8\" id=\"outline-link-H8\">Percutaneous exposure</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">Heterosexual partners</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">Men who have sex with men</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">Perinatal transmission</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">Health care workers</a></li></ul></li><li><a href=\"#H13\" id=\"outline-link-H13\">PATHOGENESIS OF LIVER DISEASE</a><ul><li><a href=\"#H14\" id=\"outline-link-H14\">Cellular immune responses</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">HIV-associated immune activation</a></li><li><a href=\"#H16\" id=\"outline-link-H16\">Activation of hepatic stellate cells</a></li><li><a href=\"#H17\" id=\"outline-link-H17\">HIV and apoptosis</a></li><li><a href=\"#H18\" id=\"outline-link-H18\">HCV-associated proinflammatory cytokines</a></li></ul></li><li><a href=\"#H19\" id=\"outline-link-H19\">EFFECT OF HIV ON THE NATURAL HISTORY OF HCV</a><ul><li><a href=\"#H20\" id=\"outline-link-H20\">Viral clearance</a></li><li><a href=\"#H21\" id=\"outline-link-H21\">Fibrosis progression rates</a><ul><li><a href=\"#H46114182\" id=\"outline-link-H46114182\">- Risk factors for progression</a></li><li><a href=\"#H10494880\" id=\"outline-link-H10494880\">- Relationship of liver disease stage and clinical outcome</a></li></ul></li><li><a href=\"#H46114332\" id=\"outline-link-H46114332\">Hepatocellular carcinoma</a></li><li><a href=\"#H46115818\" id=\"outline-link-H46115818\">Hepatic decompensation</a></li><li><a href=\"#H24\" id=\"outline-link-H24\">Mortality</a></li><li><a href=\"#H46115450\" id=\"outline-link-H46115450\">Effect of ART on HCV progression</a></li></ul></li><li><a href=\"#H27\" id=\"outline-link-H27\">EFFECT OF HCV ON THE NATURAL HISTORY OF HIV</a><ul><li><a href=\"#H1660499362\" id=\"outline-link-H1660499362\">HIV progression</a></li><li><a href=\"#H3616073095\" id=\"outline-link-H3616073095\">Other comorbidities</a></li></ul></li><li><a href=\"#H28\" id=\"outline-link-H28\">SCREENING FOR HCV INFECTION</a><ul><li><a href=\"#H29\" id=\"outline-link-H29\">Chronic infection</a></li><li><a href=\"#H30\" id=\"outline-link-H30\">Acute HCV infection</a></li><li><a href=\"#H31\" id=\"outline-link-H31\">Screening for other hepatitis viruses</a></li></ul></li><li><a href=\"#H32\" id=\"outline-link-H32\">HCV AND RISK OF HEPATOTOXICITY WITH ART</a></li><li><a href=\"#H1147018587\" id=\"outline-link-H1147018587\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H33\" id=\"outline-link-H33\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=bone-and-calcium-disorders-in-hiv-infected-patients\" class=\"medical medical_review\">Bone and calcium disorders in HIV-infected patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-natural-history-of-chronic-hepatitis-c-virus-infection\" class=\"medical medical_review\">Clinical manifestations and natural history of chronic hepatitis C virus infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-treatment-of-acute-hepatitis-c-virus-infection-in-adults\" class=\"medical medical_review\">Clinical manifestations, diagnosis, and treatment of acute hepatitis C virus infection in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-and-evaluation-of-chronic-hepatitis-c-virus-infection\" class=\"medical medical_review\">Diagnosis and evaluation of chronic hepatitis C virus infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=direct-acting-antivirals-for-the-treatment-of-hepatitis-c-virus-infection\" class=\"medical medical_review\">Direct-acting antivirals for the treatment of hepatitis C virus infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-and-transmission-of-hepatitis-c-virus-infection\" class=\"medical medical_review\">Epidemiology and transmission of hepatitis C virus infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-of-cardiovascular-disease-and-risk-factors-in-hiv-infected-patients\" class=\"medical medical_review\">Epidemiology of cardiovascular disease and risk factors in HIV-infected patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=evaluation-of-the-hiv-infected-patient-with-chronic-hepatitis-c-virus-infection\" class=\"medical medical_review\">Evaluation of the HIV-infected patient with chronic hepatitis C virus infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hiv-associated-neurocognitive-disorders-epidemiology-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">HIV-associated neurocognitive disorders: Epidemiology, clinical manifestations, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=immunizations-in-hiv-infected-patients\" class=\"medical medical_review\">Immunizations in HIV-infected patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=noninvasive-assessment-of-hepatic-fibrosis-overview-of-serologic-and-radiographic-tests\" class=\"medical medical_review\">Noninvasive assessment of hepatic fibrosis: Overview of serologic and radiographic tests</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-kidney-disease-in-hiv-positive-patients\" class=\"medical medical_review\">Overview of kidney disease in HIV-positive patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=predictors-of-response-to-antiviral-therapy-for-chronic-hepatitis-c-virus-infection\" class=\"medical medical_review\">Predictors of response to antiviral therapy for chronic hepatitis C virus infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prevention-of-hepatitis-b-virus-and-hepatitis-c-virus-infection-among-healthcare-providers\" class=\"medical medical_review\">Prevention of hepatitis B virus and hepatitis C virus infection among healthcare providers</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prevention-of-hepatitis-b-virus-infection-in-the-hiv-infected-adult\" class=\"medical medical_review\">Prevention of hepatitis B virus infection in the HIV-infected adult</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=screening-for-chronic-hepatitis-c-virus-infection\" class=\"medical medical_review\">Screening for chronic hepatitis C virus infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-hepatitis-c-virus-infection\" class=\"medical medical_society_guidelines\">Society guideline links: Hepatitis C virus infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=techniques-and-interpretation-of-measurement-of-the-cd4-cell-count-in-hiv-infected-patients\" class=\"medical medical_review\">Techniques and interpretation of measurement of the CD4 cell count in HIV-infected patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-chronic-hepatitis-c-virus-infection-in-the-hiv-infected-patient\" class=\"medical medical_review\">Treatment of chronic hepatitis C virus infection in the HIV-infected patient</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=vertical-transmission-of-hepatitis-c-virus\" class=\"medical medical_review\">Vertical transmission of hepatitis C virus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=when-to-initiate-antiretroviral-therapy-in-hiv-infected-patients\" class=\"medical medical_review\">When to initiate antiretroviral therapy in HIV-infected patients</a></li></ul></div></div>","javascript":null}